![Reimar Schlingensiepen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Reimar Schlingensiepen
Director Ejecutivo en AudioCure Pharma GmbH .
Cargos activos de Reimar Schlingensiepen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AudioCure Pharma GmbH
![]() AudioCure Pharma GmbH Pharmaceuticals: MajorHealth Technology AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany. | Director Ejecutivo | 22/05/2017 | - |
Historial de carrera de Reimar Schlingensiepen
Antiguos cargos conocidos de Reimar Schlingensiepen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
JADO Technologies GmbH
![]() JADO Technologies GmbH Drugstore ChainsRetail Trade JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany. | Director Ejecutivo | 01/01/2010 | 17/04/2014 |
Isarna Therapeutics GmbH
![]() Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Director de Operaciones | 01/01/1998 | - |
Director Financiero/CFO | 01/01/1998 | - | |
Fundador | 01/01/1998 | - |
Estadísticas
Internacional
Alemania | 4 |
Operativa
Chief Executive Officer | 2 |
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Sectorial
Health Technology | 3 |
Retail Trade | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Isarna Therapeutics GmbH
![]() Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
JADO Technologies GmbH
![]() JADO Technologies GmbH Drugstore ChainsRetail Trade JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany. | Retail Trade |
AudioCure Pharma GmbH
![]() AudioCure Pharma GmbH Pharmaceuticals: MajorHealth Technology AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany. | Health Technology |